Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020 This bill requires the Food and Drug Administration to regulate in vitro clinical tests (i.e., tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body in order to provide information about a disease, condition, or treatment for a disease or condition).
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (25)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404 Saving Access to Laboratory Services Act, S. 4449, HR 8188
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404 Saving Access to Laboratory Services Act, S. 4449, HR 8188
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Issues related to T cells, COVID testing, pandemic preparedness and immune medicine H.R. 6102 and S. 3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions H.R. 5745, COVID-19 Access to Testing and Support for Immune Response Research Act of 2021 S. 3062 Departments of Labor, HHS, and Education, and Related Agencies Appropriations Act, FY2022
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
Issues related to T cells, COVID testing, and immune medicine. H.R. 6102 and S.3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions H.R.5745 - COVID-19 Access to Testing and Support for Immune Response Research Act of 2021
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
Issues related to T cells, COVID testing, and immune medicine. H.R. 6102 and S.3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
COVID-19 Response. S.3404: VALID Act of 2020.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Pharmacy
Immunosuppressive drug coverage implementation. S.3404: VALID Act of 2020.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2021 · second_quarter · Medicare/Medicaid
Medicare treatment of outpatient reimbursement for laboratory tests. H.R.5800: Ban Surprise Billing Act. S.3404 VALID Act of 2020.
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Health Issues
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Issues related to the reauthorization of the FDA drug and device user fee programs
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
Issues related to T cells, COVID testing, and immune medicine. H.R. 6102 and S.3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
H.R. 6102 and S.3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues Reauthorization of the FDA drug and device user fee programs Schrems II, government lobbying activities pertaining to data privacy COVID-19 response; White House COVID-19 Response Team's call to private business
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, White House Office
2021 · first_quarter · Medical/Disease Research/Clinical Labs
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
Issues related to diagnostic testing; The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404); The Access to TESTs Act (HR 747).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Medical/Disease Research/Clinical Labs
Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
COVID-19 Response. S.3404: VALID Act of 2020.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Pharmacy
Immunosuppressive drug coverage implementation. S.3404: VALID Act of 2020.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2021 · first_quarter · Medicare/Medicaid
Medicare treatment of outpatient reimbursement for laboratory tests. H.R.5800: Ban Surprise Billing Act. S.3404 VALID Act of 2020.
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)
Client expense: $490,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Health Issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)
Client expense: $490,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Health Issues
H.R. 6102 and S.3404; The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020; all provisions
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
S.734, Internet of Things Cybersecurity Improvement Act of 2019, creates national standards for cybersecurity for products purchased by the federal government; S.142, American Data Dissemination Act of 2019 - creates data privacy rules; S.189, Social Media Privacy Protection and Consumer Rights Act of 2019; draft legislation and HHS proposed rules to create new value base care arrangement safe harbors under Stark and Anti-Kickback Statutes and educate key staff on FDA regulation of device service; S.3404, H.R.6102, the Verifying Accurate Leading-edge IVCT Development Act 2020 - legislation to modernize regulation of lab tests; S. 3548 CARES Act regarding enhanced provider funding and medical device shortage provisions. COVID-19 Testing - PCR molecular, serology testing coverage, payment, and funding; S.4473 and H.R.7956, Critical Medical Infrastructure Right-to-Repair Act of 2020.
Client expense: $1,010,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
S.734, Internet of Things Cybersecurity Improvement Act of 2019, creates national standards for cybersecurity for products purchased by the federal government; S.142, American Data Dissemination Act of 2019 - creates data privacy rules; S.189, Social Media Privacy Protection and Consumer Rights Act of 2019; draft legislation and HHS proposed rules to create new value base care arrangement safe harbors under Stark and Anti-Kickback Statutes and educate key staff on FDA regulation of device service; S.3404, H.R.6102, the Verifying Accurate Leading-edge IVCT Development Act 2020 - legislation to modernize regulation of lab tests; S. 3548 CARES Act regarding enhanced provider funding and medical device shortage provisions. COVID-19 Testing - PCR molecular, serology testing coverage, payment, and funding; S.4473 and H.R.7956, Critical Medical Infrastructure Right-to-Repair Act of 2020.
Client expense: $950,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
Advocacy on health care issues related to genetics and genetic testing, including H.R. 3235 - Access to Genetic Counselor Services Act of 2019; H.R.4393 - Advancing Access to Precision Medicine Act; and S. 3404/HR 6102 - Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
S 3404, VALID Act and regulation of pharmacogenomic tests.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Issues related to S. 3404, VALID Act. Monitored issues related to the implementation of P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to S. 1895, the Lower Healthcare Cost Act including Surprise Medical Billing, issues related to H.R. 861, the End Surprise Billing Act, H.R. 5800, The Ban Surprise Billing Act; issues related to EKRA; H.R. 925 / H.R. 8406, The HEROES Act, issues related to COVID-19 testing and provider relief. H.R. 133, the Consolidated Appropriations Act of 2021, including surprise medical bill and COVID-19 testing.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing; H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time; Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation; Federal policy relating to drug development, including potential legislation known as Cures 2.0; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill; and Title I of Division BB of the Consolidated Appropriations Act of 2021, Pub. L. 116-260, provisions relating to surprise billing.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Monitor implementation of H.R. 6201, the Families First Coronavirus Response Act (Public Law 116-127), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 diagnostic tests Monitor implementation of H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act, the CARES Act, (Public Law 116-136), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 diagnostic tests, laboratory data collection and reimbursement under PAMA, and laboratory data reporting Federal policy relating to implementation of anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Public Law 115-271 H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests The Public Readiness and Emergency Preparedness Act (PREP Act) and COVID-19 liability protection for frontline health care providers, including CLIA-licensed laboratories and their personnel H.R. 8496, the SPEEDY COVID-19 Tests Act, relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing H.R. 133, Consolidated Appropriations Act, 2021 (Public Law 116-260), and provisions related to clinical laboratory testing for COVID-19, and Medicare reimbursement for pathology services
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Policies related to diagnostic testing and diagnostic testing capacity; The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404); ), Consolidated Appropriations Act, 2021 (H.R. 133).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Surprise medical billing and access to colon cancer screening provisions within H.R. 133, the Consolidated Appropriations Act 2021; H.R. 6102/S. 3404 - VALID Act; issues related to COVID-19 pandemic response and clinical laboratories
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Client expense: $210,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
No Surprises Act (H.R. 133) Verifying Accurate Leading-edge IVCT Development Act of 2020 (S.3404, H.R. 6102) Temporary Reciprocity to Ensure Access to Treatment Act (S.4421, H.R. 8283) Rare Cancer Awareness, Research, and Treatment Act of 2020 (draft, not yet introduced) Government response to COVID-19, including liability reforms and supply chain issues
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)
Client expense: $490,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Medicare/Medicaid
Issues related to lab analysis and review of diagnostics and lab developed tests, including VALID Act of 2020 (H.R. 6102/S. 3404), Eliminating Kickbacks in Recovery Act of 2018, and the 21st Century Cures 2.0 Concept Paper.
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Issues related to lab analysis and review of diagnostics and lab developed tests, including the VALID Act of 2020 (H.R. 6102/S. 3404), Eliminating Kickbacks in Recovery Act of 2018, and 21st Century Cures 2.0 Concept Paper.
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
H.R.6102 and S.3404, Verifying Accurate Leading-edge IVCT Development Act of 2020, all provisions
Client expense: Not reported · Firm income: Not reported
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R.6102 and S.3404, Verifying Accurate Leading-edge IVCT Development Act of 2020, all provisions
Client expense: Not reported · Firm income: Not reported
2020 · fourth_quarter · Health Issues
H.R.6102 and S.3404, Verifying Accurate Leading-edge IVCT Development Act of 2020, all provisions
Client expense: Not reported · Firm income: Not reported
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing and vaccine supply chain issues.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · fourth_quarter · Health Issues
Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; H.R. 8406, the HEROES Act, provisions in Section 307 relating to coverage of COVID-19 testing H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time; Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation; Federal policy relating to drug development, including potential legislation known as Cures 2.0; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill; and H. R. 133, the Consolidated Appropriations Act of 2021, provisions in Title I of Division BB relating to surprise billing.
Client expense: $650,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R.6102/S.3404, Verifying Accurate Leading-Edge IVCT Development (VALID) Act
Client expense: Not reported · Firm income: $65,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R. 6102/S. 3404, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.3512, Verified Innovative Testing in American Laboratories (VITAL) Act Laboratory test supply shortages
Client expense: Not reported · Firm income: $37,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE